Recently, results from the “ATTR-ACT” trial have been published, representing the first randomized study evaluating Tafamidis (commercially known as Vyndaqel) for the treatment of both wild-type and hereditary forms of transthyretin cardiac amyloidosis. This evidence concerns the gene TTR and cardiac amyloidosis.